Publications by authors named "T Reinert"
Monoclonal antibody (mAbs) therapeutics cannot evade the occurrence of adverse effects. Thus, mAbs are commonly triggering immune responses corresponding to the expression of antidrug antibodies. Antidrug antibodies can neutralize mAbs, leading to their inhibition and hasten clearance, which dramatically hampers their therapeutic effects.
View Article and Find Full Text PDFArticle Synopsis
- Circulating tumor DNA (ctDNA) can help detect residual cancer after treatment, but its low levels make detection tough; tumor-informed whole-genome sequencing (WGS) offers a solution using numerous mutations for better ctDNA identification.
- * In a study with 144 stage III colorectal cancer patients and 1283 plasma samples, WGS created a unique mutational fingerprint that improved ctDNA detection and demonstrated excellent reproducibility across labs.
- * Results showed that ctDNA detection post-surgery and post-chemotherapy strongly predicted cancer recurrence, often identifying it months before standard imaging; the study highlights the potential for WGS to track cancer evolution and treatment effects.*
Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improves outcome for patients with estrogen receptor-positive (ER+) metastatic breast cancer, but drug resistance and thus disease progression inevitably occur. Herein, we aimed to identify genomic alterations associated with combined CDK4/6i and endocrine therapy resistance, and follow the levels of specific mutations in longitudinal circulating tumor DNA (ctDNA) for early detection of progression. From a cohort of 86 patients with ER+ metastatic breast cancer we performed whole exome sequencing or targeted sequencing of paired tumor (N = 8) or blood samples (N = 5) obtained before initiation of combined CDK4/6i and endocrine therapy and at disease progression.
View Article and Find Full Text PDFArticle Synopsis
- Breast cancer is the top cause of cancer-related deaths among women globally, yet there's a lack of research on metastatic breast cancer (MBC) in low- and middle-income countries, particularly regarding the genomic features of Brazilian patients.
- This study analyzed tumor samples from 328 Brazilian women with estrogen receptor-positive (ER+)/HER2-negative MBC to assess mutations in the PI3K-AKT pathway and other key genetic drivers using advanced sequencing techniques from 2020 to 2023.
- Findings indicated a 39.3% mutation prevalence in the PI3K-AKT pathway, with older patients (over 50) showing increased mutation rates and 6.1% of samples harboring mutations in the PTEN gene, especially in
Background: Circulating tumor DNA (ctDNA) has emerged as a promising tool for early cancer detection and minimal residual disease monitoring. However, the biology underlying ctDNA release and its variation across cancer types and histologies remains poorly understood. This study investigated the biology behind ctDNA shedding in colorectal cancer.
View Article and Find Full Text PDF